Filtros de búsqueda

Lista de obras de Patrizia Vici

"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome.

scientific article published on 18 February 2016

1st Evidence-based Italian consensus conference on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinosis from ovarian cancer.

artículo científico publicado en 2017

5-Fluorouracil, Epirubicin, and BCNU (FEB) in Advanced Measurable Gastric Cancer ⬇️

artículo científico publicado el 1 de junio de 1990

A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression

scientific article published on 03 July 2019

A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer.

artículo científico publicado en 2016

A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study

artículo científico publicado en 2018

A multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node-positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study

artículo científico publicado en 2011

A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study

artículo científico publicado en 2011

A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab

artículo científico publicado en 2019

A phase II trial of docetaxel and vinorelbine in patients with advanced breast cancer previously treated with anthracyclines

artículo científico publicado en 2008

A prospective randomized trial of doxorubicinversus idarubicin in the treatment of advanced breast cancer

artículo científico publicado en 1989

A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience

artículo científico publicado en 2017

Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide

artículo científico publicado en 2003

Altered expression of FAS system is related to adverse clinical outcome in stage I-II breast cancer patients treated with adjuvant anthracycline-based chemotherapy

artículo científico publicado en 2004

Analysis of the ATR-Chk1 and ATM-Chk2 pathways in male breast cancer revealed the prognostic significance of ATR expression. ⬇️

artículo científico publicado en 2017

Analysis of the hippo transducers TAZ and YAP in cervical cancer and its microenvironment.

artículo científico publicado en 2016

Androgen receptor and antiandrogen therapy in male breast cancer ⬇️

artículo científico

Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting

artículo científico publicado en 2017

Anthropometric, metabolic and molecular determinants of human epidermal growth factor receptor 2 expression in luminal B breast cancer

artículo científico publicado en 2015

Antiandrogen therapy in metastatic male breast cancer: results from an updated analysis in an expanded case series.

artículo científico publicado en 2014

Aromatase inhibitors for metastatic male breast cancer: molecular, endocrine, and clinical considerations.

artículo científico

Association between AXL, Hippo Transducers, and Survival Outcomes in Male Breast Cancer ⬇️

artículo científico publicado en 2016

Autoantibodies Specific to ERα are Involved in Tamoxifen Resistance in Hormone Receptor Positive Breast Cancer

scientific article published on 19 July 2019

Bevacizumab as first-line treatment in HER2-negative advanced breast cancer: pros and cons

artículo científico publicado en 2016

Bevacizumab in ovarian cancer: A critical review of phase III studies

artículo científico publicado en 2016

Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin.

artículo científico publicado en 2015

Body mass index and treatment outcomes following neoadjuvant therapy in women aged 45 y or younger: Evidence from a historic cohort

artículo científico publicado en 2016

Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab.

artículo científico publicado en 2018

Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer.

artículo científico publicado en 2017

Breast cancer "tailored follow-up" in Italian oncology units: a web-based survey

artículo científico publicado en 2014

Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic review

artículo científico publicado en 2013

Breast cancer risk after exposure to fertility drugs

artículo científico

Breast carcinomas with low amplified/equivocal HER2 by Ish: potential supporting role of multiplex ligation-dependent probe amplification

artículo científico publicado en 2017

Cancer stem cells: are they responsible for treatment failure?

artículo científico publicado en 2014

Coexisting YAP expression and TP53 missense mutations delineates a molecular scenario unexpectedly associated with better survival outcomes in advanced gastric cancer

artículo científico publicado en 2018

Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients

artículo científico publicado en 2019

Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study

artículo científico publicado en 2018

Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study

artículo científico publicado en 2018

Correction: The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer

artículo científico publicado en 2015

Current role and safety profile of aromatase inhibitors in early breast cancer

artículo científico

DNA Damage and Repair Biomarkers in Cervical Cancer Patients Treated with Neoadjuvant Chemotherapy: An Exploratory Analysis

artículo científico publicado en 2016

DNA damage repair and survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy.

artículo científico publicado en 2017

Deep sequencing and pathway-focused analysis revealed multigene oncodriver signatures predicting survival outcomes in advanced colorectal cancer

artículo científico publicado en 2018

Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting

artículo científico publicado en 2019

Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer.

artículo científico publicado en 2013

Does granulocyte colony-stimulating factor worsen anemia in early breast cancer patients treated with epirubicin and cyclophosphamide?

artículo científico publicado en 2006

Double-blind randomized phase III study comparing a mixture of natural agents versus placebo in the prevention of acute mucositis during chemoradiotherapy for head and neck cancer

artículo científico publicado en 2017

Dual-time 18F-FDG PET/CT for the detection of liver metastases in breast cancer

scientific article published on 01 December 2018

ESAS and FACT-B in eribulin-treated metastatic breast cancer patients: a multicenter, prospective and observational study

artículo científico publicado en 2017

Early direct and indirect impact of quadrivalent HPV (4HPV) vaccine on genital warts: a systematic review

artículo científico publicado en 2015

Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials

artículo científico publicado en 2018

Effect of filgrastim on serum lactate dehydrogenase and alkaline phosphatase values in early breast cancer patients

artículo científico publicado en 2004

Effect of targeted agents on the endocrine response of breast cancer in the neoadjuvant setting: a systematic review

artículo científico publicado en 2015

Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer

artículo científico publicado en 2013

Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study

artículo científico

Efficacy of chemotherapy in metastatic male breast cancer patients: a retrospective study

artículo científico publicado en 2015

Efficacy of pertuzumab in combination with trastuzumab and a taxane in first-line treatment for metastatic breast cancer (MBC): A multicenter, retrospective, observational study

Emerging biological treatments for uterine cervical carcinoma.

artículo científico publicado en 2014

Emerging role of cancer stem cells in the biology and treatment of ovarian cancer: basic knowledge and therapeutic possibilities for an innovative approach

artículo científico publicado en 2013

Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer

article

Eribulin in Triple Negative Metastatic Breast Cancer: Critic Interpretation of Current Evidence and Projection for Future Scenarios

scientific article published on 12 October 2019

Eribulin in the treatment of advanced breast cancer: real-world scenario from 39 Italian centers - ESEMPiO study

article

Eribulin mesylate in pretreated breast cancer patients: a multicenter retrospective observational study.

artículo científico publicado en 2014

Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study

scientific article published on 07 August 2018

Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting.

artículo científico publicado en 2017

Expression of ER, PgR, HER-2, and Ki-67 in core biopsies and in definitive histological specimens in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy

scientific article published on 21 November 2019

Expression of phosphorylated Hippo pathway kinases (MST1/2 and LATS1/2) in HER2-positive and triple-negative breast cancer patients treated with neoadjuvant therapy.

artículo científico publicado en 2017

Expression of the Hippo transducer TAZ in association with WNT pathway mutations impacts survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy

artículo científico publicado en 2018

FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort.

artículo científico publicado en 2013

Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study

artículo científico publicado en 2017

Feasibility of Eribulin Mesylate in older patients with locally advanced or metastatic breast cancer: A post-hoc analysis of the ESEMPiO study

artículo científico publicado en 2019

Fertility Preservation and Reproductive Health in Patients Undergoing Hematopoietic Stem Cell Transplantation

artículo científico publicado en 2019

Fertility drugs, reproductive strategies and ovarian cancer risk.

artículo científico publicado en 2014

First-line treatment with epirubicin and vinorelbine in metastatic breast cancer

artículo científico publicado en 2002

Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial.

artículo científico publicado en 2017

GLUT 1 receptor expression and circulating levels of fasting glucose in high grade serous ovarian cancer.

artículo científico publicado en 2017

Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients.

artículo científico publicado en 2013

HMG-CoAR expression in male breast cancer: relationship with hormone receptors, Hippo transducers and survival outcomes ⬇️

artículo científico publicado en 2016

Highly durable response to capecitabine in patient with metastatic estrogen receptor positive breast cancer: A case report

artículo científico publicado en 2019

Hot flushes in women with breast cancer: state of the art and future perspectives

artículo científico

Human papillomavirus 16 E2 interacts with neuregulin receptor degradation protein 1 affecting ErbB-3 expression in vitro and in clinical samples of cervical lesions.

artículo científico publicado en 2016

Identification of subgroups of early breast cancer patients at high risk of nonadherence to adjuvant hormone therapy: results of an Italian survey

artículo científico publicado en 2014

Immunologic treatments for precancerous lesions and uterine cervical cancer

artículo científico publicado en 2014

Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives

artículo científico publicado en 2019

Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence

artículo científico publicado en 2020

Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide

artículo científico publicado en 2005

Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: a retrospective multicenter study

artículo científico publicado en 2019

Increasing single epirubicin doses in advanced soft tissue sarcomas

artículo científico publicado en 2002

Induction of ErbB-3 expression by alpha6beta4 integrin contributes to tamoxifen resistance in ERbeta1-negative breast carcinomas

artículo científico publicado en 2008

Insulin-Sensitizers, Polycystic Ovary Syndrome and Gynaecological Cancer Risk

artículo científico publicado en 2016

Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GI

artículo científico publicado en 2019

Is the skin a sanctuary for breast cancer cells during treatment with anti-HER2 antibodies?

artículo científico publicado en 2015

Laparoscopic Debulking Surgery in the Management of Advanced Ovarian Cancer After Neoadjuvant Chemotherapy.

artículo científico

Laparoscopic versus robotic radical hysterectomy after neoadjuvant chemotherapy in locally advanced cervical cancer: a case control study.

artículo científico publicado en 2013

Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer.

artículo científico publicado en 2013

Long-Term Safety and Real-World Effectiveness of Trastuzumab in Breast Cancer

artículo científico publicado en 2019

Long-term outcome of breast cancer patients with pathologic N3a lymph node stage.

artículo científico publicado en 2017

Metabolic Determinants and Anthropometric Indicators Impact Clinical-pathological Features in Epithelial Ovarian Cancer Patients.

artículo científico publicado en 2016

Metachronous and Synchronous Cancers in Patients with Neuroendocrine Tumors

scientific article published on 10 September 2019

Metformin and breast cancer: basic knowledge in clinical context.

artículo científico

Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study

artículo científico publicado en 2019

Multicenter phase II trial of first-line docetaxel/gemcitabine in advanced breast cancer pretreated with adjuvant anthracyclines.

artículo científico publicado en 2009

Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma

scientific article published on 16 July 2019

Neoadjuvant Chemotherapy In Triple-Negative Breast Cancer: A Multicentric Retrospective Observational Study In Real-Life Setting.

artículo científico

Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial

artículo científico publicado en 2016

Niraparib in ovarian cancer: results to date and clinical potential.

artículo científico publicado en 2017

Non-pegylated liposomal Doxorubicin-cyclophosphamide in sequential regimens with taxanes as neoadjuvant chemotherapy in breast cancer patients

artículo científico publicado en 2014

Novel association with gemcitabine and docetaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracyclines: results of a multicenter phase II study

artículo científico publicado en 2004

Observational Multicenter Study on the Prognostic Relevance of Coagulation Activation in Risk Assessment and Stratification in Locally Advanced Breast Cancer. Outline of the ARIAS Trial

scientific article published on 01 April 2020

Observational study of coagulation activation in early breast cancer: development of a prognostic model based on data from the real world setting.

artículo científico publicado en 2018

Optimal tolerability and high efficacy of a modified schedule of lapatinib-capecitabine in advanced breast cancer patients

artículo científico publicado en 2013

Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study

artículo científico publicado en 2014

Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience

artículo científico publicado en 2018

Phase I–II trial of prolonged gemcitabine infusion plus paclitaxel as a biweekly schedule for advanced breast cancer patients pretreated with anthracyclines

scientific article published on 29 May 2010

Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study

artículo científico publicado en 2016

Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis

artículo científico publicado en 2015

Presurgical window of opportunity trial design as a platform for testing anticancer drugs: Pros, cons and a focus on breast cancer

artículo científico publicado en 2016

Prexasertib, a checkpoint kinase inhibitor: from preclinical data to clinical development

artículo científico publicado en 2019

Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting

artículo científico publicado en 2019

Prognostic value of (99m)Tc-sestamibi washout in predicting response of locally advanced breast cancer to neoadjuvant chemotherapy

scientific article published on 01 June 2002

Recurrence risk in small, node-negative, early breast cancer: a multicenter retrospective analysis

artículo científico publicado en 2013

Reply to Kadri Altundag: Do cut-off values of lymph node ratio and presence of perineural invasion affect survival in breast cancer patients with pathologic N3a lymph node stage?

artículo científico publicado en 2017

Risk of SARS-CoV-2 infection and disease in metastatic triple-negative breast cancer patients treated with immune checkpoint inhibitors

scientific article published on 03 June 2020

Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: results from a pooled analysis ⬇️

artículo científico publicado en 2015

Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience

artículo científico publicado en 2016

Sequential docetaxel followed by epirubicin-vinorelbine as first-line chemotherapy in advanced breast cancer

artículo científico publicado en 2005

Short course hypofractionated whole breast irradiation after conservative surgery: a single institution phase II study.

artículo científico publicado en 2017

Surgical and Oncological Outcome of Robotic Surgery Compared With Laparoscopic and Abdominal Surgery in the Management of Locally Advanced Cervical Cancer After Neoadjuvant Chemotherapy

artículo científico publicado en 2016

Targeting angiogenesis in endometrial cancer - new agents for tailored treatments.

artículo científico publicado en 2015

Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies

scientific article published on 11 April 2016

Taxanes and gemcitabine doublets in the management of HER-2 negative metastatic breast cancer: towards optimization of association and schedule

artículo científico publicado en 2008

The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy

artículo científico publicado en 2020

The HERBA Study: A Retrospective Multi-Institutional Italian Study on Patients With Brain Metastases From HER2-Positive Breast Cancer

scientific article published on 18 May 2019

The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy.

artículo científico publicado en 2014

The Hippo transducers TAZ and YAP in breast cancer: oncogenic activities and clinical implications.

artículo científico

The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer ⬇️

artículo científico publicado en 2016

The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer

artículo científico publicado en 2015

The clinical implementation of primary HPV screening

artículo científico publicado en 2016

The clinical significance of PD-L1 in advanced gastric cancer is dependent on ARID1A mutations and ATM expression

scientific article published on 24 April 2018

The sexist behaviour of immune checkpoint inhibitors in cancer therapy?

artículo científico publicado en 2017

Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy

artículo científico publicado en 2016

Trastuzumab-related cardiotoxicity in patients with nonlimiting cardiac comorbidity

scientific article published on 01 April 2019

Triple positive breast cancer: a distinct subtype?

artículo científico publicado en 2014

Triple-negative breast cancer: new perspectives for targeted therapies.

artículo científico publicado en 2015

Unusual long-lasting cutaneous complete response to lapatinib and capecitabine in a heavily pretreated HER2-positive plurimetastatic breast cancer patient.

artículo científico publicado en 2013

Vaginal atrophy in breast cancer survivors: role of vaginal estrogen therapy.

artículo científico publicado en 2012

Vitamin D supplementation and breast cancer prevention: a systematic review and meta-analysis of randomized clinical trials

artículo científico publicado en 2013

p53 status as effect modifier of the association between pre-treatment fasting glucose and breast cancer outcomes in non diabetic, HER2 positive patients treated with trastuzumab.

artículo científico publicado en 2014

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda